טוען...
Sulindac inhibits pancreatic carcinogenesis in LSL-Kras(G12D)-LSL-Trp53(R172H)-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10)
Sulindac has been identified as a competitive inhibitor of aldo-keto reductase 1B10 (AKR1B10), an enzyme that plays a key role in carcinogenesis. AKR1B10 is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and exhibits lipid substrate specificity, especially for farnesyl and geranylgeranyl....
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3765049/ https://ncbi.nlm.nih.gov/pubmed/23689354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgt170 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|